Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 10Withdrawn 2Unknown 1Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 9Myeloid 6Lymphoid 5Gastrointestinal 4Breast 4CNS 3Thoracic 2Gynecologic 2Genitourinary 2Sarcoma 1Plasma cell 1Other neoplasm 1Head & Neck 1Dermatologic 1

Conditions

Head and Neck Neoplasms 1

Interventions

Cisplatin 108Radiotherapy 45Docetaxel 44Radiotherapy, Intensity-Modulated 36Gemcitabine 31Fluorouracil 30camrelizumab 24toripalimab 21Drug Therapy 21Cetuximab 20apatinib 19Paclitaxel 16Carboplatin 16pembrolizumab 14Chemoradiotherapy 14Capecitabine 13Blood Specimen Collection 13sintilimab 12nimotuzumab 12Surveys and Questionnaires 10Surgical Procedures, Operative 10Endostatins 10Cyclophosphamide 9nedaplatin 8endostar protein 8durvalumab 8Nivolumab 8Neoadjuvant Therapy 8Induction Chemotherapy 8fludarabine 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Polymerase Chain Reaction × Head & Neck × Clear all
NCT00690872 2009-06-29

Gemcitabine and Carboplatin Followed By Laboratory-Treated T Lymphocytes in Treating Patients With Metastatic or Locally Recurrent Epstein-Barr Virus-Positive Nasopharyngeal Cancer

National Cancer Institute (NCI)

Phase 2 Unknown
35 enrolled
Head & Neck

Head and Neck Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡